Gefitinib and 5-FU for Colorectal Cancer
Author Information
Author(s): Stebbing J, Harrison M, Glynne-Jones R, Bridgewater J, Propper D
Primary Institution: Imperial College, Imperial Healthcare, NHS Trust
Hypothesis
Can gefitinib reverse fluoropyrimidine resistance in metastatic colorectal cancer?
Conclusion
Gefitinib does not sensitize patients with fluoropyrimidine refractory metastatic colorectal cancer to 5-FU chemotherapy.
Supporting Evidence
- There were no objective responses in the study.
- The stable disease rate was 37.5%.
- Median progression-free survival was 116 days.
- Median overall survival was 226 days.
- Quality of life remained unchanged compared to baseline.
Takeaway
This study tested a drug called gefitinib to see if it could help patients with a type of cancer that didn't respond to other treatments, but it didn't work.
Methodology
An open-label, non-comparative phase II study of gefitinib combined with 5-FU in 24 patients with metastatic colorectal cancer.
Limitations
The study had a small sample size and no objective responses were observed.
Participant Demographics
{"mean_age":64.3,"sex_distribution":{"male":14,"female":10},"race_distribution":{"caucasian":20,"black":3,"other":1}}
Statistical Information
Confidence Interval
95% CI: 18.80, 59.41
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website